The CH50 test measures whether the classical complement pathway can complete a full immune reaction from its early proteins through the membrane attack complex. It is a functional test, not simply a count of one protein. In a vasculitis evaluation, a low CH50 can suggest that complement is being consumed by immune complexes, that one pathway component is deficient, that complement-blocking treatment is working, or that the specimen was mishandled. The result is most useful beside C3, C4, AH50, urinalysis, kidney function, infection studies, and disease-specific antibodies. Low activity can support immune-complex conditions such as lupus or cryoglobulinemic vasculitis, but it does not identify the cause. Many patients with ANCA-associated vasculitis have normal serum CH50 even though complement activation contributes to disease inside tissues. Because complement proteins are fragile outside the body, an unexpectedly low value often needs confirmation before it is treated as a biological finding.
- CH50 tests the function of the entire classical complement pathway, including the shared terminal pathway from C3 through C9.
- A low or absent CH50 may reflect immune-complex consumption, inherited deficiency, liver disease, complement-inhibitor therapy, or sample degradation.
- A normal CH50 does not rule out vasculitis, including ANCA-associated vasculitis and disease limited to one organ.
- CH50 reference ranges vary by method and laboratory; interpret the reported interval rather than using a universal target.
- Low CH50 plus blood or protein in urine, rapidly changing kidney function, fever, purpura, or nerve symptoms needs prompt clinical follow-up.
Table of Contents
- How the CH50 Test Works
- What a Low CH50 Result Can Mean
- How CH50 Helps in a Vasculitis Workup
- Interpreting CH50 With C3, C4, and AH50
- Normal and High CH50 Results
- Sample Handling and Repeat Testing
- Follow-Up Tests and Urgent Signs
How the CH50 Test Works
Complement is a network of blood proteins that marks microbes and damaged material, recruits inflammatory cells, and can punch holes in target membranes. It can begin through three routes: the classical, lectin, and alternative pathways. These routes converge at C3 and share the terminal components C5 through C9.
CH50 stands for total hemolytic complement activity of the classical pathway. Traditional assays mix patient serum with antibody-coated red blood cells and measure how well the serum lyses them. Modern laboratories may use liposome or enzyme-based versions, but the principle is similar: every required classical and terminal component must work well enough for the reaction to finish.
This makes CH50 different from measuring C3 or C4 concentration. A person can have an individual protein within the numerical reference range yet have impaired function. Conversely, one low component can pull the entire CH50 down because the pathway acts like a chain. If one essential link is missing or consumed, total function falls.
Results may be reported in units per milliliter, percent activity, or an assay-specific value. Some laboratories report “undetectable,” “low,” “normal,” or “high.” There is no single worldwide normal range because reagents, endpoints, and calibration differ.
CH50 is often ordered for one of three broad reasons:
- suspected immune-complex consumption in an autoimmune or infectious disease;
- suspected inherited or acquired complement deficiency;
- monitoring the pharmacologic blockade produced by selected complement inhibitors.
In vasculitis, the first question is usually whether a low value reflects active immune-complex disease. Yet the other two possibilities must remain visible, because the clinical implications are very different. Treating an inherited deficiency as an autoimmune flare would be a major error, as would overlooking infection in someone whose complement is being consumed.
A general total complement activity interpretation explains broad uses. In a vasculitis evaluation, the result becomes more specific only after it is combined with symptoms, urine findings, serology, and tissue evidence.
What a Low CH50 Result Can Mean
A low CH50 means the classical-to-terminal complement sequence did not produce normal functional activity in the sample. It does not say why. Four explanations account for most clinically important results.
Consumption from immune activation occurs when complement proteins are repeatedly used faster than the liver can replace them. Immune complexes can activate the classical pathway in systemic lupus erythematosus, mixed cryoglobulinemia, infection-related glomerulonephritis, endocarditis, and selected immune-complex vasculitides. C3, C4, or both may also be low, depending on the pathway and intensity.
Inherited complement deficiency is less common but important. Deficiency of C1, C2, or C4 can produce very low CH50 with a normal AH50 because the alternative pathway remains intact. Deficiency of C3 or terminal components C5 through C9 can lower both CH50 and AH50. Early classical deficiencies are associated with lupus-like autoimmunity, while terminal pathway defects increase susceptibility to invasive Neisseria infections.
Acquired loss or reduced production can occur with severe liver dysfunction, protein-losing kidney or intestinal disease, extensive inflammation, or selected hematologic conditions. The pattern may involve several proteins rather than one isolated component.
Therapeutic blockade is expected with drugs that inhibit C5 or other critical complement steps. A profoundly suppressed functional assay may confirm adequate pathway blockade, depending on the drug and the monitoring method. The target and acceptable residual activity are treatment-specific; a vasculitis reference range should not be used as a dosing rule.
A fifth explanation is not biological: preanalytical loss of activity. Complement can activate or degrade in a tube that remains warm too long, is separated late, or is transported improperly. This can make a healthy pathway look deficient.
The degree of reduction matters, but it does not create a diagnosis. A mildly low CH50 with a normal C3, C4, and AH50 may warrant repeat testing before extensive investigation. An undetectable CH50 on two carefully handled samples, especially with recurrent meningococcal infection or a strong autoimmune phenotype, deserves a structured complement-deficiency workup.
How CH50 Helps in a Vasculitis Workup
CH50 is most helpful for separating immune-complex vasculitis from conditions that usually do not lower circulating complement. It acts as a directional clue rather than a disease label.
Low complement activity can support disorders such as:
- cryoglobulinemic vasculitis, often with a disproportionately low C4;
- lupus vasculitis or lupus nephritis;
- infection-associated immune-complex vasculitis;
- hypocomplementemic urticarial vasculitis syndrome;
- selected forms of membranoproliferative glomerulonephritis;
- immune-complex disease related to hepatitis B, hepatitis C, or endocarditis.
The accompanying findings determine which possibility rises. Purpura, joint pain, weakness, neuropathy, kidney abnormalities, low C4, rheumatoid factor, and detectable cryoglobulins point toward mixed cryoglobulinemia. Hives lasting longer than 24 hours, burning or bruising lesions, low C1q, and anti-C1q antibodies may suggest hypocomplementemic urticarial vasculitis. ANA, anti-double-stranded DNA antibodies, low C3 and C4, and lupus-compatible organ disease point toward systemic lupus erythematosus.
By contrast, serum complement levels are often normal in ANCA-associated vasculitis. GPA and microscopic polyangiitis are called pauci-immune because kidney biopsy usually shows little immunoglobulin or complement deposition. Research has established an important role for alternative-pathway activation and C5a in their biology, but that tissue-level mechanism does not mean routine CH50 must be low. A normal result therefore cannot exclude AAV, and a low result should make clinicians consider overlap, infection, immune-complex disease, advanced kidney loss, or another cause.
The distinction is clinically useful but not absolute. A minority of patients with AAV have low serum complement, and low values may associate with more severe kidney disease in some cohorts. That finding still needs context. It does not turn CH50 into a diagnostic or activity marker for ANCA vasculitis.
For kidney presentations, CH50 should be read with urinalysis, creatinine, urine protein, ANCA, anti-GBM antibodies, ANA-related tests, hepatitis testing, and often kidney biopsy. A vasculitis blood test panel helps establish the broader differential, while biopsy shows whether deposits are immune-complex, anti-GBM, or pauci-immune.
Two examples show why context matters. A patient with palpable purpura, numb feet, protein and blood in the urine, a very low C4, low CH50, positive rheumatoid factor, and hepatitis C risk has a pattern that makes mixed cryoglobulinemic vasculitis a leading concern. The same low CH50 in a teenager with repeated meningococcal infections, no inflammatory urine findings, and a persistently absent AH50 points instead toward a terminal complement deficiency. Both results are “low,” but they lead to completely different testing and treatment.
A third scenario is a patient with destructive sinus disease, lung nodules, red-cell casts, and strongly positive PR3-ANCA whose CH50 is normal. That normal value does not weaken a coherent GPA diagnosis. It simply shows that routine circulating classical-pathway function is preserved. The mistake would be to expect every complement-driven inflammatory mechanism to produce low serum complement. Tissue activation, short-lived fragments, and pathway-specific signaling can be biologically important without lowering the total functional reserve measured in blood.
This distinction also prevents over-monitoring. Repeating CH50 frequently in ANCA-associated vasculitis usually adds less value than following kidney function, urine sediment, pulmonary findings, and treatment toxicity. In immune-complex disease, by contrast, serial CH50 may be useful when previous values consistently tracked clinically meaningful flares.
Interpreting CH50 With C3, C4, and AH50
CH50 becomes much more informative when paired with individual components and alternative pathway function. AH50, also called AP50 in some laboratories, measures the alternative pathway and the shared terminal sequence.
| CH50 | AH50 | Pattern to consider |
|---|---|---|
| Low | Normal | Early classical pathway deficiency or classical pathway consumption |
| Normal | Low | Alternative pathway component deficiency or selective alternative pathway dysfunction |
| Low | Low | C3 or terminal pathway deficiency, broad consumption, severe loss, or sample problem |
| Normal | Normal | Major classical and alternative pathway function is intact; some regulatory or lectin-pathway defects remain possible |
C3 and C4 concentrations refine these patterns. Low C4 with relatively preserved C3 often points toward strong classical-pathway use, as seen in mixed cryoglobulinemia and some lupus activity. Low C3 with normal or mildly reduced C4 may suggest alternative-pathway activation, infection-related disease, or selected complement-mediated kidney disorders. Both low can reflect broad immune-complex activation.
The C3 and C4 vasculitis pattern is easier to understand when viewed alongside CH50: concentrations show how much protein is present, while functional assays show whether the pathway can complete its task.
No screening table is definitive. A low CH50 with low C4 can arise from inherited C4 deficiency or active consumption. Repeating the sample during clinical stability and measuring individual components can distinguish a persistent constitutional pattern from a fluctuating disease-related pattern.
If both CH50 and AH50 are repeatedly absent, the next step may include individual C1q, C2, C3, C4, C5-C9, factor B, factor D, properdin, or regulatory proteins. Genetic testing is usually reserved for a phenotype and laboratory pattern that support inherited deficiency. It is not the first response to one mildly low result.
Normal and High CH50 Results
A normal CH50 means the classical and terminal pathways functioned within that laboratory’s reference interval at the time of collection. It does not prove that complement is inactive in tissues, exclude a mild deficiency, or rule out autoimmune disease.
Normal CH50 is common in:
- ANCA-associated vasculitis;
- giant cell arteritis and polymyalgia rheumatica;
- many cases of Behçet disease;
- isolated cutaneous vasculitis;
- sarcoidosis and other inflammatory disorders;
- immune-complex disease between flares or after treatment.
The result is reassuring mainly when the clinical question is a major classical pathway deficiency. It has less exclusion value for localized or episodic vasculitis.
A high CH50 generally means increased overall complement capacity rather than a dangerous “toxic” level. Complement proteins can behave as acute-phase reactants, so activity may rise during infection, inflammation, obesity, metabolic disease, or tissue injury. Laboratories may report high activity when the sample lyses target cells more efficiently than their reference population.
High CH50 is nonspecific and rarely identifies a disease. It cannot distinguish infection from autoimmune inflammation and should not be used as a stand-alone flare marker. CRP, ESR, symptoms, imaging, organ function, and disease-specific markers usually provide more actionable information.
When monitoring an immune-complex disease, normalization can reflect reduced consumption and treatment response. However, the same value may also normalize because the inflammatory episode resolved spontaneously or because the underlying condition changed. Trends should be interpreted against objective organ outcomes, such as improved urine sediment, stable kidney function, healing skin lesions, or reduced neuropathic progression.
Sample Handling and Repeat Testing
CH50 is unusually sensitive to collection and transport. Complement continues to react after blood leaves the body. If the sample is not processed and frozen according to the laboratory’s instructions, activity may fall before testing.
Common preanalytical problems include:
- delayed separation of serum from cells;
- prolonged room-temperature storage;
- repeated freeze-thaw cycles;
- thawing during transport;
- use of the wrong tube or specimen type;
- contamination or severe hemolysis.
Requirements differ by laboratory, but many centers ask for serum that is promptly separated and frozen. The ordering site should follow the receiving laboratory’s exact instructions rather than relying on a generic protocol.
Repeat testing is sensible when the value is unexpectedly low and does not match C3, C4, AH50, symptoms, or prior results. The repeat should use a fresh specimen handled under controlled conditions. If CH50 normalizes, specimen degradation becomes likely. If it remains markedly low, further pathway testing is justified.
Medication history matters. C5 inhibitors intentionally suppress CH50 and AH50 because both assays require the terminal pathway. Other complement-targeted agents can produce different patterns. Plasma exchange, fresh frozen plasma, major transfusion, severe infection, and immunosuppressive treatment can also alter results over time.
Timing affects interpretation in episodic immune-complex disease. A sample drawn during a rash, nephritic flare, or systemic inflammatory episode may show consumption that disappears in remission. This is useful when the clinical pattern repeats, but it also means one normal value outside a flare cannot rule out prior complement activation.
The safest rule is to verify biology before building a diagnosis around a surprising low functional result. The more discordant the number is with the rest of the case, the more important specimen quality becomes.
Follow-Up Tests and Urgent Signs
Follow-up depends on why CH50 was ordered. A low result in suspected vasculitis may lead to C3, C4, AH50, C1q, anti-C1q antibodies, ANA-related antibodies, cryoglobulins, rheumatoid factor, hepatitis testing, blood cultures, and kidney studies. A low result in someone with recurrent invasive infections may lead toward immunology referral and individual complement component testing.
Useful questions for the clinician or laboratory include:
- Was the specimen processed and frozen within the required time?
- Are C3, C4, and AH50 also abnormal?
- Is the pattern new or persistent on older records?
- Does the patient take a complement inhibitor or recently receive plasma?
- Are there signs of immune-complex disease, liver dysfunction, protein loss, or infection?
- Has urinalysis shown blood, protein, or casts?
- Would kidney or skin biopsy clarify the mechanism?
For possible complement deficiency, ask about recurrent meningococcal disease, unusual pneumococcal infection, family history, and lupus-like autoimmunity. Vaccination and preventive antibiotic decisions belong with an immunology or infectious-disease specialist once the defect is confirmed.
Urgent evaluation is needed for rapidly reduced urine output, rising creatinine with blood in urine, coughing blood, severe breathlessness, rapidly spreading purpura, new foot or wrist drop, severe abdominal pain, confusion, fever with low blood pressure, or signs of meningococcal infection such as sudden fever, headache, neck stiffness, and a rapidly evolving rash. CH50 is a clue; the organ or infection emergency determines the immediate action.
A low CH50 should ultimately lead to a narrower question, not a broader label. Is complement being consumed, is a pathway component missing, is treatment blocking the pathway, or did the sample lose activity? Answering that question requires the paired pattern and the clinical setting.
References
- Complement Testing – Complement Deficiency and Anticomplement Therapeutic Response Monitoring 2025 (Guideline)
- Complement Blood Test 2024 (Official Resource)
- The complement system and human autoimmune diseases 2023 (Review)
- Complement Deficiency 2023 (Review)
- Inherited defects in the complement system 2022 (Review)
- Role of complement activation in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis 2022 (Review)
Disclaimer
This article provides general education and cannot diagnose vasculitis, complement deficiency, infection, or a treatment response. CH50 results require interpretation with specimen handling, C3, C4, AH50, medications, symptoms, and organ testing. Seek urgent care for rapidly worsening kidney, lung, neurologic, or severe infection symptoms.
